|
1
|
Priyadarsini KI: The chemistry of
curcumin: From extraction to therapeutic agent. Molecules.
19:20091–20112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar P, Sulakhiya K, Barua CC and Mundhe
N: TNF-α, IL-6 and IL-10 expressions, responsible for disparity in
action of curcumin against cisplatin-induced nephrotoxicity in
rats. Mol Cell Biochem. 431:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baghbani F, Chegeni M, Moztarzadeh F,
Hadian-Ghazvini S and Raz M: Novel ultrasound-responsive
chitosan/perfluorohexane nanodroplets for image-guided smart
delivery of an anticancer agent: Curcumin. Mater Sci Eng C.
74:186–193. 2017. View Article : Google Scholar
|
|
4
|
Cheng A-L, Hsu C-H, Lin J-K, Hsu M-M, Ho
Y-F, Shen T-S, Ko J-Y, Lin J-T, Lin B-R, Ming-Shiang W, et al:
Phase I clinical trial of curcumin, a chemopreventive agent, in
patients with high-risk or pre-malignant lesions. Anticancer Res
21B. 2895–2900. 2001.
|
|
5
|
Liu Z, Liu J, Zhao L, Geng H, Ma J, Zhang
Z, Yu D and Zhong C: Curcumin reverses benzidine-induced
epithelial-mesenchymal transition via suppression of ERK5/AP-1 in
SV-40 immortalized human urothelial cells. Int J Oncol.
50:1321–1329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maher DM, Bell MC, O'Donnell EA, Gupta BK,
Jaggi M and Chauhan SC: Curcumin suppresses human papillomavirus
oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits
benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog.
50:47–57. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park W, Amin AR, Chen ZG and Shin DM: New
perspectives of curcumin in cancer prevention. Cancer Prev Res
(Phila). 6:387–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Panahi Y, Darvishi B, Ghanei M, Jowzi N,
Beiraghdar F and Varnamkhasti BS: Molecular mechanisms of curcumins
suppressing effects on tumorigenesis, angiogenesis and metastasis,
focusing on NF-κB pathway. Cytokine Growth Factor Rev. 28:21–29.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wright JS: Predicting the antioxidant
activity of curcumin and curcuminoids. J Mol Struct. 591:207–217.
2002. View Article : Google Scholar
|
|
10
|
Scharstuhl A, Mutsaers HAM, Pennings SWC,
Szarek WA, Russel FGM and Wagener FADTG: Curcumin-induced
fibroblast apoptosis and in vitro wound contraction are regulated
by antioxidants and heme oxygenase: Implications for scar
formation. J Cell Mol Med. 13:712–725. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brzóska K, Stępkowski TM and Kruszewski M:
Basal PIR expression in HeLa cells is driven by NRF2 via
evolutionary conserved antioxidant response element. Mol Cell
Biochem. 389:99–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zaman MS, Chauhan N, Yallapu MM, Gara RK,
Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, et al:
Curcumin nanoformulation for cervical cancer treatment. Sci Rep.
6:200512016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gallardo M and Calaf GM: Curcumin inhibits
invasive capabilities through epithelial mesenchymal transition in
breast cancer cell lines. Int J Oncol. 49:1019–1027. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
OMS, . Cervical cancer estimated
incidence, Mortality and prevalence worldwide in 2012. http://gco.iarc.fr/today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-16.pdfMarch
1–2019
|
|
16
|
OMS, . Human papillomavirus (HPV) and
cervical cancer. 2016, http://www.who.int/mediacentre/factsheets/fs380/en/March
1–2019
|
|
17
|
zur Hausen H: Human papillomavirus &
cervical cancer. Indian J Med Res. 130:2092009.PubMed/NCBI
|
|
18
|
Senapati R, Senapati NN and Dwibedi B:
Molecular mechanisms of HPV mediated neoplastic progression. Infect
Agent Cancer. 11:592016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niu G, Wang D, Pei Y and Sun L: Systematic
identification of key genes and pathways in the development of
invasive cervical cancer. Gene. 618:28–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carrillo D, Muñoz JP, Huerta H, Leal G,
Corvalán A, León O, Calaf GM, Urzúa U, Boccardo E, Tapia JC, et al:
Upregulation of PIR gene expression induced by human papillomavirus
E6 and E7 in epithelial oral and cervical cells. Open Biol.
7:1701112017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Licciulli S, Luise C, Zanardi A, Giorgetti
L, Viale G, Lanfrancone L, Carbone R and Alcalay M: Pirin
delocalization in melanoma progression identified by high content
immuno-detection based approaches. BMC Cell Biol. 11:52010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zeng Q, Li X, Bartlam M, Wang G, Pang H
and Rao Z: Purification, crystallization and preliminary X-ray
analysis of human pirin. Acta Crystallogr D Biol Crystallogr.
59:1496–1498. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pang H, Bartlam M, Zeng Q, Miyatake H,
Hisano T, Miki K, Wong L-L, Gao GF and Rao Z: Crystal structure of
human pirin: An iron-binding nuclear protein and transcription
cofactor. J Biol Chem. 279:1491–1498. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu F, Rehmani I, Esaki S, Fu R, Chen L,
de Serrano V and Liu A: Pirin is an iron-dependent redox regulator
of NF-κB. Proc Natl Acad Sci USA. 110:9722–9727. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Komai K, Niwa Y, Sasazawa Y and Simizu S:
Pirin regulates epithelial to mesenchymal transition independently
of Bcl3-Slug signaling. FEBS Lett. 589:738–743. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mishra A and Das BC: Curcumin as an
anti-human papillomavirus and anti-cancer compound. Future Oncol.
11:2487–2490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tennant JR: Evaluation of the trypan blue
technique for determination of cell viability. Transplantation.
2:685–694. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rodriguez LG, Wu X and Guan JL:
Wound-healing assay. Methods Mol Biol. 294:23–29. 2005.PubMed/NCBI
|
|
30
|
Thacker PC and Karunagaran D: Curcumin and
emodin down-regulate TGF-β signaling pathway in human cervical
cancer cells. PLoS. 10:e01200452015. View Article : Google Scholar
|
|
31
|
Roy M and Mukherjee S: Reversal of
resistance towards cisplatin by curcumin in cervical cancer cells.
Asian Pac J Cancer Prev. 15:1403–1410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shao Z-M, Shen Z-Z, Liu C-H, Sartippour
MR, Go VL, Heber D and Nguyen M: Curcumin exerts multiple
suppressive effects on human breast carcinoma cells. Int J Cancer.
98:234–240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Calaf GM, Echiburú-Chau C, Wen G, Balajee
AS and Roy D: Effect of curcumin on irradiated and
estrogen-transformed human breast cell lines. Int J Oncol.
40:436–442. 2012.PubMed/NCBI
|
|
34
|
Meissner JD: Nucleotide sequences and
further characterization of human papillomavirus DNA present in the
CaSki, SiHa and HeLa cervical carcinoma cell lines. J Gen Virol.
80:1725–1733. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Licciulli S, Cambiaghi V, Scafetta G,
Gruszka AM and Alcalay M: Pirin downregulation is a feature of AML
and leads to impairment of terminal myeloid differentiation.
Leukemia. 24:429–437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Derycke LD and Bracke ME: N-cadherin in
the spotlight of cell-cell adhesion, differentiation,
embryogenesis, invasion and signalling. Int J Dev Biol. 48:463–476.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bolós V, Peinado H, Pérez-Moreno MA, Fraga
MF, Esteller M and Cano A: The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: A comparison with Snail and E47 repressors. J Cell
Sci. 116:499–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Adhikary A, Chakraborty S, Mazumdar M,
Ghosh S, Mukherjee S, Manna A, Mohanty S, Nakka KK, Joshi S, De A,
et al: Inhibition of epithelial to mesenchymal transition by
E-cadherin up-regulation via repression of slug transcription and
inhibition of E-cadherin degradation: Dual role of scaffold/matrix
attachment region-binding protein 1 (SMAR1) in breast cancer cells.
J Biol Chem. 289:25431–25444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu WS, You RI, Cheng CC, Lee MC, Lin TY
and Hu CT: Snail collaborates with EGR-1 and SP-1 to directly
activate transcription of MMP 9 and ZEB1. Sci Rep. 7:177532017.
View Article : Google Scholar : PubMed/NCBI
|
